Roche–Nurix Partnership Targets BTK-Degrader bexobrutideg for Blood Cancers

On 8 June 2026, Roche Holding AG and U.S. biotech Nurix Therapeutics announced an exclusive global licensing and collaboration agreement to co-develop and co-commercialize bexobrutideg (NX-5948), an oral Bruton’s tyrosine kinase (BTK) degrader. The deal provides Nurix with a $700 million upfront payment and potential milestone payments that could bring total consideration to up to $2.3 billion. Development costs will be shared 60 % by Roche and 40 % by Nurix; U.S. profits and losses will be split equally, while Roche will lead commercialization outside the United States. The transaction is subject to antitrust clearance (Hart-Scott-Rodino) and is expected to close in the third quarter of 2026.

Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood CancersRoche Holding AG stock (CH0012032048): collaboration deal with Nurix highlights oncology focusBioSpaceRoche signs up to $2.3 billion deal with Nurix for BTK degrader BexobrutidegRoche's $2.3 Billion Nurix Deal Sends Shares MovingRoche and Nurix Therapeutics to partner in $2.3bn dealRoche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg

Approved BTK inhibitors—Imbruvica (AbbVie/J&J), Calquence (AstraZeneca), Brukinsa (BeOne Medicines, $3.9 billion sales in 2025), and Jaypirca (Eli Lilly)—block kinase activity but leave the BTK protein scaffold intact, fostering resistance mutations. Bexobrutideg employs targeted protein degradation to eliminate BTK entirely, potentially overcoming resistance in patients who have progressed on existing inhibitors.

Roche signs up to $2.3 billion deal with Nurix for BTK degrader BexobrutidegRoche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B dealRoche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood CancersRoche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader BexobrutidegBioSpaceRoche and Nurix Therapeutics to partner in $2.3bn deal

• Roche Holding AG – Swiss multinational pharmaceutical leader, expanding its hematology pipeline.

Roche Holding AG stock (CH0012032048): collaboration deal with Nurix highlights oncology focus

• Nurix Therapeutics – California-based biotech specializing in protein-degrader platforms.

BioSpace

• Levi Garraway – Chief Medical Officer & Head of Global Product Development, Roche.

Roche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg

• Arthur T. Sands – President & Chief Executive Officer, Nurix Therapeutics.

Roche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg

• 8 June 2026 – Public announcement and parallel investor disclosure.

Roche Holding AG stock (CH0012032048): collaboration deal with Nurix highlights oncology focus

• Summer 2026 – Initiation of Phase 3 trial for second-line chronic lymphocytic leukemia (CLL).

Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood Cancers

• Q3 2026 – Anticipated regulatory clearance and deal closing.

Roche Holding AG stock (CH0012032048): collaboration deal with Nurix highlights oncology focus

• ~2030 – Projected market entry, contingent on trial outcomes and approvals.

Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood Cancers

• Phase 1a data (cut March 2025) showed an 80.9 % objective response rate in 47 heavily pre-treated, relapsed/refractory CLL patients, including those previously exposed to BTK and BCL-2 inhibitors.

Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal

• The CLL market is forecast to grow from $12 billion (2024) to $16 billion (2035).

Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal

• BTK inhibitor class generated multi-billion-dollar revenues, underscoring the commercial relevance of a differentiated approach.

Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal

The collaboration adds a protein-degrader modality to Roche’s oncology portfolio, complementing its existing B-cell-targeted agents and extending reach into immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis). Analysts note that the deal’s cost-sharing structure retains commercial upside for Nurix while leveraging Roche’s late-stage development and global distribution capabilities.

Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood Cancers

Roche will fund 60 % of development costs and assume worldwide commercialization outside the U.S.; both parties will share U.S. profit and loss equally. Nurix will receive royalties in the low- to high-teens on non-U.S. sales. The agreement reflects Roche’s strategy to diversify beyond aging blockbusters and to secure next-generation hematology candidates.

Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood Cancers

The primary clinical uncertainty is durability: progression-free survival in the BTK-pretreated cohort remains untested. Observers caution that early response rates, while impressive, must translate into sustained benefit to justify the multibillion-dollar investment.

Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal

Most sources cite a total deal value of up to $2.3 billion, but a Biospace report references a figure of up to $3 billion, indicating a discrepancy in public disclosures. Additionally, detailed development plans for the immunology and neurology indications have not been disclosed.

Roche Holding AG stock (CH0012032048): collaboration deal with Nurix highlights oncology focus

• “Our goal is to create new possibilities for patients with challenging diseases. We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases. We are proud to join forces with Nurix to accelerate these potential breakthroughs.” — Levi Garraway, CMO, Roche

Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg

• “ Levi Garraway, Chief Medical Officer And Head Of Global Product Development, Roche “We believe Roche is the ideal partner to help translate the promise of targeted protein degradation into meaningful impact for patients worldwide.” — Arthur T. Sands, CEO, Nurix Therapeutics

Roche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg

• “The single number worth tracking from this trial forward is the durability endpoint — specifically, progression-free survival in the BTK-pretreated cohort.” — Source: Roche press release

Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal

• “We view the partnership as sensible and validating for [bexobrutideg’s] clinical profile, including its potential safety differentiation,” — Analyst, Truist Securities

BioSpace

• “We are also excited to explore combination regimens utilising selected agents from Roche’s portfolio of successful B-cell malignancy drugs.” — Arthur T. Sands, CEO, Nurix Therapeutics

Roche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg

The Phase 3 CLL trial will commence in summer 2026, followed by regulatory filings pending trial outcomes. If successful, bexobrutideg could launch around 2030, positioning Roche to compete in a BTK market projected to exceed $16 billion by 2035. Ongoing data on durability and expansion into immunology and neurology will shape the partnership’s long-term impact.

Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood Cancers